Districts first Leukocytaphersis Transfusion and operation on a patient who had a rare  fatal bleeding disorder

Districts first Leukocytaphersis Transfusion and operation on a patient who had a rare  fatal bleeding disorder

One of our big strengths as an institution is our collaboration and partnership. Our multidisciplinary discussions, planning and perfect execution produce excellent results which create better patient outcomes and overall excellence in all that we do. There were two such successful interdisciplinary efforts.

Hyperleukocytosis, defined as a WBC count >1,00,000/mm3, is a complication seen in 5%–20% of patients with acute leukaemia. Which can be treated with Leukocytapheresis is a procedure by which WBCs are collected and plasma, platelets, and RBCs are returned to the patient. Before the procedure, the WBC count of the patient was  7,60,000/mm3 which is way more than the average count. After the procedure, the count decreased to about  3,50,000/mm3. We would like to thank the team of Transfusion medicine especially the doctors Dr Lekshmi,  Dr Priya.   

 Acquired haemophilia A (AHA), is a rare and potentially fatal bleeding disorder. Caused by antibodies attacking against the coagulation factor( VIII (FVIII)), it occurs in both men and women without a previous history of bleeding.

Treatment of bleeds, Surgical interventions and other invasive procedures should be carried out at a special centre. The patient was in severe pain and rightly no intervention was attempted outside in the absence of factor support. 

Yesterday, Team Orthopaedics did the operation to release all blood collected inside the patient tissue. This patient had AHA under the cover of factor eight bypass activity agents. Feiba, which is an Anti-Inhibitor Coagulant Complex approved for use in haemophilia was arranged and provided by colleagues at the Kottayam Medical College, Dr Irshad. We’re grateful to the doctors Dr Koshy George and Dr Subin from the orthopaedics department who did this risky operation so perfectly.